Emergence of “FemTech” within the Sexual and Reproductive Health landscape
摘要截稿:
全文截稿: 2024-05-01
影响因子: 2.819
期刊难度:
CCF分类: 无
中科院JCR分区:
• 大类 : 医学 - 2区
• 小类 : 妇产科学 - 2区
Overview
The term ‘FemTech’ (short for female technology) refers to technologies and innovations created to address aspects of health and well-being for those with female reproductive organs. FemTech includes, among other things, mobile apps, wearables, internet-connected medical devices, materials science innovations, at-home diagnostics, virtual clinics, and digital communities. FemTech innovations hold the potential to support bodily autonomy for users, offer culturally sensitive solutions, and individually tailor services. FemTech often comes with private sector investment which can bring accelerated innovation, yet may also allow market incentives to dominate data collection and reporting. Furthermore, these products are often less regulated than products used clinically. The deadline for submission of a letter of intent is May 1, 2024.
------------
Guest editors:
------------
Chelsea B Polis, PhDPopulation Council, New York, United StatesRebecca Simmons, PhD, MPHThe University of Utah, Utah, United StatesPatty Cason, RN, MS, FNPUniversity of California, Los Angeles, California, United StatesAngel M. Foster, DPhil, MD, AMUniversity of Ottawa, Ontario, Canada
------------
Special issue information:
------------
For this special issue, we seek submissions pertaining to FemTech products and services in the SRH landscape.
------------
• We impose no restrictions on geographical focus areas of interest.• We will accept a variety of manuscript types, including original research articles, reports highlighting programmatic examples and policy debates, and evidence-informed commentaries.• We seek submissions focused on FemTech products or services relevant to contraception, fertility tracking, or abortion. Note: while this call does not focus on pregnancy management or infertility, in recognition of the intersecting nature of these topics with our focus outcomes, we will consider papers on those topics if they are related to contraception and abortion.• We will prioritize submissions focused on measurable effects and outcomes (positive or negative), and topic areas that are understudied and can advance equitable and person-centered access to SRH care.• We are particularly interested in independent examinations of FemTech products and services that have been developed with support from venture capital or private equity funding, given the distinct scientific, ethical, and regulatory environments in which such technologies may potentially arise (as compared with technologies developed through more standard public health funding streams).• We are not seeking submissions related to user acceptability testing or piloting technologies.Examples of topics of interest include, but are not limited to:• Assessments of the extent to which FemTech for SRH is robustly evaluated for effectiveness or safety.• Analyses on how FemTech for SRH is marketed, including use of social media in relation to these products.• Impacts of FemTech for SRH on timing of reproductive events (e.g., pregnancy recognition) or decision-making (e.g., abortion).• Examinations of the regulatory environment for FemTech for SRH, especially submissions tailored for an audience of SRH researchers and providers.• Explorations around how expansion of the use of FemTech for SRH may modify use of other products (e.g., contraceptive methods) and outcomes (e.g., pregnancies).• Considerations around privacy and digital security for web-connected FemTech for SRH.• The potential for FemTech for SRH to address gaps in data on health by gender.• Implications of FemTech for SRH on concerns such as health equity and the digital divide.